Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stomach Cancer: early-phase trial registry
8 of 16 indexed Stomach Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Stomach Cancer: 16 US clinical trials tracked, 8 recruiting.
Stomach Cancer is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Stanford University, running 2 of these trials.
Enrollment posture brief
Registry condition stomach-cancer
OPEN 8 | RECR 50% | LATE 0 | EARLY 9 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Stomach Cancer lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stomach Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stomach Cancer is recruiting above its size-band peers.
8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Stomach Cancer trials is spread across many organizations.
Stanford University accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Stomach Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 16 trials that report a genuine target (sentinel values excluded). 10 of those (62.5%) plan for fewer than 100 participants.
-
Stomach Cancer splits between interventional and observational designs.
11 interventional and 5 observational studies make up this index (68.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Stanford University
NCT01048281
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
NCT05187182
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
NCT07070466
Avutometinib and Defactinib in Diffuse Gastric Cancer
Ryan H. Moy, MD, PhD
NCT06487221
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
University of Kansas Medical Center
NCT03488667
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
National Cancer Institute (NCI)
NCT03027427
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
M.D. Anderson Cancer Center
NCT00525785
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
NCT00780494
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
NYU Langone Health
NCT00858338
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center
NCT03604653
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Stomach Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stomach Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stomach Cancer page
16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Stomach Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stanford University sponsors the most Stomach Cancer trials on record, review their full trial history before evaluating a specific study. See Stanford University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stomach Cancer condition card totals 16 registered trials; most-linked intervention 5-Fluorouracil; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.